NASDAQ:TMDX TransMedics Group (TMDX) Stock Price, News & Analysis $134.01 +2.56 (+1.95%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About TransMedics Group Stock (NASDAQ:TMDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TransMedics Group alerts:Sign Up Key Stats Today's Range$132.10▼$135.8250-Day Range$87.72▼$143.0452-Week Range$55.00▼$177.37Volume574,764 shsAverage Volume1.39 million shsMarket Capitalization$4.53 billionP/E Ratio98.54Dividend YieldN/APrice Target$127.33Consensus RatingModerate Buy Company OverviewTransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Read More… TransMedics Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreTMDX MarketRank™: TransMedics Group scored higher than 31% of companies evaluated by MarketBeat, and ranked 829th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingModerate Buy Consensus RatingTransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageTransMedics Group has only been the subject of 3 research reports in the past 90 days.Read more about TransMedics Group's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth43.00% Earnings GrowthEarnings for TransMedics Group are expected to grow by 43.00% in the coming year, from $1.00 to $1.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is 99.35, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.89.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is 99.35, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.49.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 19.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TransMedics Group's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.99% of the float of TransMedics Group has been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in TransMedics Group has recently decreased by 2.72%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted24.99% of the float of TransMedics Group has been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in TransMedics Group has recently decreased by 2.72%, indicating that investor sentiment is improving. News and Social Media2.2 / 5News Sentiment1.01 News SentimentTransMedics Group has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for TransMedics Group this week, compared to 18 articles on an average week.Search InterestOnly 19 people have searched for TMDX on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,512,613.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TransMedics Group's insider trading history. Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address TMDX Stock News HeadlinesMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayTransMedics Group and two other mid-cap names just posted dominant performances in Q1, smashing forecasts set by Wall Street analysts.June 12, 2025 | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $95,902.80 in StockJune 11, 2025 | insidertrades.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.June 30 at 2:00 AM | Brownstone Research (Ad)3 Medical Technology Stocks Outperforming in 2025 (TMDX)Three med-tech stocks, TransMedics, Insulet, and GRAIL, are outperforming the market and their sector while forming bullish technical patterns.June 9, 2025 | marketbeat.com3 High-Growth Stocks Traders Love and Investors Should Watch (TMDX)These three small stocks carry significant risk, but that volatility has served traders well this year; now it's time for long-term investors to take a look...June 5, 2025 | marketbeat.com2 Stocks That Have Doubled This Year and Are Still Worth BuyingJune 30 at 4:21 AM | fool.comTMDX - TransMedics Group Inc Sustainability - MorningstarJune 27 at 5:08 PM | morningstar.comMTransMedics Group Inc. (TMDX) Stock Price Today - WSJJune 26, 2025 | wsj.comSee More Headlines TMDX Stock Analysis - Frequently Asked Questions How have TMDX shares performed this year? TransMedics Group's stock was trading at $62.35 on January 1st, 2025. Since then, TMDX stock has increased by 116.7% and is now trading at $135.11. View the best growth stocks for 2025 here. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) posted its quarterly earnings data on Thursday, May, 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. The business's quarterly revenue was up 48.2% on a year-over-year basis. Read the conference call transcript. When did TransMedics Group IPO? TransMedics Group (TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Broadcom (AVGO), Arista Networks (ANET) and CrowdStrike (CRWD). Company Calendar Last Earnings5/08/2025Today6/30/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:TMDX CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$127.33 High Stock Price Target$178.00 Low Stock Price Target$75.00 Potential Upside/Downside-3.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$1.36 Trailing P/E Ratio96.65 Forward P/E Ratio131.45 P/E GrowthN/ANet Income$35.46 million Net Margins10.03% Pretax Margin10.25% Return on Equity21.88% Return on Assets6.15% Debt Debt-to-Equity Ratio1.92 Current Ratio9.10 Quick Ratio8.32 Sales & Book Value Annual Sales$441.54 million Price / Sales10.07 Cash Flow$1.65 per share Price / Cash Flow79.89 Book Value$6.81 per share Price / Book19.30Miscellaneous Outstanding Shares33,820,000Free Float31,456,000Market Cap$4.45 billion OptionableOptionable Beta2.10 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:TMDX) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.